Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-14. (Canceled)

15. (Previously presented) A method to determine the breast cancer stage of a ductal lavage or fine needle aspiration sample from a subject comprising

assaying said sample for expression of 5 or more of the genes in any one of Tables 2-5, which genes are correlated with one or more stages of breast cancer, and

determining the breast cancer stage of said sample based on the level of expression of said genes.

16. (Previously presented) The method of claim 15 wherein said assaying comprises preparing mRNA from said sample.

17. (Previously presented) The method of claim 15 wherein said mRNA is amplified.

18. (Previously presented) The method of claim 15 wherein said assaying comprises detecting expression by use of an array.

19. (Previously presented) The method of claim 15 wherein said assaying comprises detecting expression by use of a microarray comprising polynucleotides which hybridize to said genes.

20. (Currently amended) ~~A method to determine the breast cancer stage of a ductal lavage or fine needle aspiration sample from a subject comprising~~ The method of claim 15 wherein

said expression of 5 or more genes is ~~assaying said sample for expression of one or more genes are~~ correlated with ADH, DCIS, and/or IDC~~, and~~

~~determining the breast cancer stage of said sample based on the level of expression of said one or more gene~~.

21. (Previously presented) The method of claim 15 wherein said one or more genes are correlated with normal or abnormal cells.

22-29. (Canceled)

30. (Previously presented) The method of claim 19 wherein said array comprises polynucleotides which hybridize to more than 5 of the genes in any one of Tables 2-5.

31. (Previously presented) The method of claim 15 wherein said subject is human.

32. (Previously presented) The method of claim 15 wherein said subject is afflicted with, or suspected of having, breast cancer.

33. (Previously presented) The method of claim 19 wherein said array comprises polynucleotides which hybridize to more than five of the genes in Table 2.

34. (Previously presented) The method of claim 19 wherein said array comprises polynucleotides which hybridize to more than five of the genes in Table 3.

35. (Previously presented) The method of claim 19 wherein said array comprises polynucleotides which hybridize to more than five of the genes in Table 4.

36. (Previously presented) The method of claim 19 wherein said array comprises polynucleotides which hybridize to more than five of the genes in Table 5.

37. (Previously presented) The method of claim 15 wherein said sample is a microdissected sample.

38. (Previously presented) The method of claim 37 wherein said sample is microdissected via laser capture microdissection.

39. (Previously presented) The method of claim 20 wherein said one or more genes are correlated with ADH.

40. (Previously presented) The method of claim 20 wherein said one or more genes are correlated with DCIS.

41. (Previously presented) The method of claim 20 wherein said one or more genes are correlated with IDC.

42. (canceled)

43. (canceled)

44. (Previously presented) The method of claim 20 wherein said assaying comprises preparing mRNA from said sample.

45. (Previously presented) The method of claim 20 wherein said mRNA is amplified.

46. (Previously presented) The method of claim 20 wherein said assaying comprises detecting expression by use of an array.

47. (Previously presented) The method of claim 20 wherein said subject is human.

48. (Previously presented) The method of claim 20 wherein said subject is afflicted with, or suspected of having, breast cancer.